Vir Biotechnology, Inc. - Common Stock, $0.0001 par value (VIR)

CUSIP: 92764N102

Q2 2022 13F Holders as of 30 Jun 2022

Security type / class
Equity / Common Stock, $0.0001 par value
Total 13F shares
86,086,454
Total 13F value
$2,193,070,491
Holder snapshot 6 visible 7 signals
Share change
+5,735,503
Put/Call ratio
82%
SEC-reported price per share
$25.47
Number of holders
201
Value change
+$146,002,800
Number of buys
121
Open additional details 1 more signal available
Number of sells
94
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
168,432,200

Security key

92764N102

Report period

Q2 2022

Institutions

201

Top holders

10

VIR full security history Ownership snapshot Full 13F holder table Newer quarter: Q3 2022 Previous quarter: Q1 2022 Vir Biotechnology, Inc. SEC filings Vir Biotechnology, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of VIR - Vir Biotechnology, Inc. - Common Stock, $0.0001 par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
SB INVESTMENT ADVISERS (U...
Disclosed value leader
SB INVESTMENT ADVISERS (U...
Comparable rows
15/15
Latest evidence
31 Mar 2022
13F Lead comparable stake: 13% Showing 1-6 of 15 holder rows.

Quick read

SB INVESTMENT ADVISERS (UK) LTD leads the comparable SEC ownership view at 13%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens SB INVESTMENT ADVISERS (UK) LTD's linked filing trail.
Comparable ownership Top 5
SB INVESTMENT ADVISERS (UK) LTD 13%
VANGUARD GROUP INC 4.6%
Temasek Holdings (Private) Ltd 3.3%
BlackRock Finance, Inc. 3.2%
MILLENNIUM MANAGEMENT LLC 2.8%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
SB INVESTMENT ADVISERS (UK) LTD
13F
Company
13F
13%
$571,412,000
22,216,644 shares
 — 31 Mar 2022
VANGUARD GROUP INC
13F
Company
13F
4.6%
$199,546,000
7,758,397 shares
 — 31 Mar 2022
Temasek Holdings (Private) Ltd
13F
Company
13F
3.3%
$144,097,663
5,602,553 shares
 — 31 Mar 2022
BlackRock Finance, Inc.
13F
Company
13F
3.2%
$138,790,000
5,396,184 shares
 — 31 Mar 2022
MILLENNIUM MANAGEMENT LLC
13F
Company
13F
2.8%
$122,124,000
4,748,194 shares
 — 31 Mar 2022
Capital International Investors
13F
Company
13F
2.6%
$111,355,000
4,329,516 shares
 — 31 Mar 2022
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2022

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
201
Shares
86,086,454
Rows available
201
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2022 vs Q1 2022 Across Filers

Q1 2022 holders
191
Q2 2022 holders
201
Holder diff
10
Investor Q1 2022 Shares Q2 2022 Shares Share Diff Share Chg % Q1 2022 value Q2 2022 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .